TY - JOUR
T1 - Risk of recurrent venous thromboembolism after a first oestrogen-associated episode
T2 - Data from the REVERSE cohort study
AU - Le Gal, Grégoire
AU - Kovacs, Michael J.
AU - Carrier, Marc
AU - Do, Kimberley
AU - Kahn, Susan R.
AU - Wells, Philip S.
AU - Anderson, David A.
AU - Chagnon, Isabelle
AU - Solymoss, Susan
AU - Crowther, Mark
AU - Righini, Marc
AU - Lacut, Karine
AU - White, Richard H.
AU - Vickars, Linda
AU - Rodger, Marc
PY - 2010/9
Y1 - 2010/9
N2 - The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3-6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5-7 months. The risk of recurrent VTE during follow-up was compared between women users and non users of oestrogen at the time of index VTE. Among the 646 patients included, 314 were women, of them 67 were current users of oestrogen at the time of their VTE: 49 were on oral contraceptives and 18 on post-menopausal hormone replacement therapy (HRT). No significant association was found between oestrogen exposure, either oral contraceptives or HRT, and a lower risk of recurrent VTE after adjustment for age, or analysis restricted to women in the same age range as oestrogen contraceptives and HRT users, respectively. The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use.
AB - The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3-6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5-7 months. The risk of recurrent VTE during follow-up was compared between women users and non users of oestrogen at the time of index VTE. Among the 646 patients included, 314 were women, of them 67 were current users of oestrogen at the time of their VTE: 49 were on oral contraceptives and 18 on post-menopausal hormone replacement therapy (HRT). No significant association was found between oestrogen exposure, either oral contraceptives or HRT, and a lower risk of recurrent VTE after adjustment for age, or analysis restricted to women in the same age range as oestrogen contraceptives and HRT users, respectively. The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use.
UR - http://www.scopus.com/inward/record.url?scp=77956621009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956621009&partnerID=8YFLogxK
U2 - 10.1160/TH09-10-0685
DO - 10.1160/TH09-10-0685
M3 - Article
C2 - 20539910
AN - SCOPUS:77956621009
SN - 0340-6245
VL - 104
SP - 498
EP - 503
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 3
ER -